“Bridging the Translational Valley of Death in Auditory Gene and Drug Therapies." Donald Hodges, Ellie Khadir, Aurore Marie, Marie-Pierre Pasdelou, Gaelle Naert, Rami Tzafriri
Background: Each year, exciting scientific discoveries are presented at ARO and yet the number of hearing therapies can be counted on one hand. High failure rates are common to all therapy areas and are increasingly attributed to translational gap or valley of death. The translational valley refers to the disconnect between basic scientific discoveries (bench research) and their successful application as safe and effective therapies for patients.
Methods: We reviewed our collective experiences in supporting drug development from discovery to first-in-man IND.
Results: Failure may arise due to anatomical and physiological animal model limitations, statistical methodology and emphasis, and the chosen biomarkers.
Discovery phase research in cell-culture rodents or even non-human primates may not translate into humans owing physiological and/or anatomical differences. Biological effects can vary across species and relative to humans owing to significant differences in cochlear size, hair cell distribution, hearing range, and regenerative capacity compared to humans. The round window membrane and cochlear fluids differ in permeability between rodents, guinea pigs, minipigs, and humans limiting the ability to extrapolate pharmacokinetics across species.
Cultural and incentive misalignments are also a factor. Academic publications focus on novelty, whereas industry focuses on reproducibility, scalability, and clinical translation. Early findings are often overinterpreted, emphasizing statistical significance without addressing reproducibility or effect-size, leading to fragile foundations for drug programs.
Standard preclinical endpoints such as ABR (auditory brainstem response) and DPOAE (distortion product otoacoustic emissions) cannot recapitulate human subjective measures (speech discrimination, tinnitus perception). Moreover, histopathological evidence hair cell loss or synaptopathy observed post-mortem in animals is difficult to align with clinical symptoms.
Novel modalities invariably lead to regulatory and strategic uncertainty. Off-target effects, immune responses, and vector-related toxicity to Gene & cell therapies are poorly modeled in small animals. Lack of species cross-reactivity to biologics/oligonucleotides forces reliance on surrogate systems, which may not capture cochlear distribution or toxicity. Regulatory uncertainty amplifies the translational gap for inner ear therapeutics. Regulators demand GLP-compliant data, but guidelines don’t always address emerging modalities, forcing toxicologists to design bespoke studies that still may not be predictive.
Operational and logistical challenges can make the difference between success and failure. Formulations may be incompatible with clinical reality. Manufacturing at clinical grade (GMP) introduces formulation, stability, and delivery problems not seen in at the bench. Trial design can also be key. Recruiting the right patients, defining endpoints, and ensuring statistical power are complex, costly and slow processes.
Conclusions: The transnational gap is persistent in drug development due to a combination of scientific, cultural, methodological and logistical complexities. Translational success requires close integration of basic scientists, translational experts (toxicologists, and regulatory experts), early in lead development.